Clinical Presentation and 6-Month Outcomes of Patients with Peripartum Cardiomyopathy in Indonesia
DOI: https://doi.org/10.2147/ijgm.s447214
IF: 2.145
2024-03-21
International Journal of General Medicine
Abstract:Hawani Sasmaya Prameswari, Triwedya Indra Dewi, Melawati Hasan, Erwan Martanto , † Astri Astuti, Aninka Saboe, Charlotte Johanna Cool Department of Cardiology and Vascular Medicine, Faculty of Medicine, Padjadjaran University, Bandung, West Java, Indonesia †Erwan Martanto passed away on 17 August 2023 Correspondence: Hawani Sasmaya Prameswari, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia, Email Background: Due to the rarity of peripartum cardiomyopathy (PPCM) globally, baseline characteristic data for PPCM patients are still scarce. Therefore, this study aims to determine the baseline characteristics and 6-month outcomes of PPCM patients in Indonesia. Methods: From January 2014 to December 2021, all PPCM patients aged ≥ 18 years who were admitted to Dr. Hasan Sadikin General Hospital in Bandung, Indonesia, participated in this single-center, prospective cohort study. All patients were re-evaluated within 6 months of PPCM diagnosis. Results: A total of 138 patients with PPCM were admitted to Dr. Hasan Sadikin General Hospital in Bandung. The mean age of all patients was 30.4 ± 6.4 years old. Approximately 60% patients were multipara and had preeclampsia. All guideline-directed medical therapy for heart failure was received by most patients, excluding mineralocorticoid receptor antagonists (25.2%) and bromocriptine (14.1%). The neonatal mortality rate was 5.1%. Among those who survived, 61.2% had normal weight, 31.8% had low birth weight, and 7% had very low birth weight. At the 6-month follow-up, 6.7% of the patients died, 63.3% recovered, and 1.9% were rehospitalized. Conclusion: The present study found a high incidence of PPCM in Indonesia. Our patients frequently had preeclampsia, which contributed to the higher rate of miscarriage and low birth weight. Our liberal use of beta-blockers and ACEi/ARB may have contributed to the higher 6-month recovery rate than that in other countries. Keywords: peripartum cardiomyopathy, preeclampsia, PPCM, recovery, registry Peripartum cardiomyopathy (PPCM) is an uncommon form of heart failure (HF) defined by left ventricular (LV) systolic dysfunction and left ventricular ejection fraction (LVEF) less than 45% in women during pregnancy or within months following parturition. 1,2 The global prevalence of this condition is estimated to be 144 events per 100,000 births. 3 It varies markedly across regions, with the highest incidence in Nigeria (1 in 102 births) 4 and the lowest prevalence in Japan (1 in 15.533 births). 5 Although rare, and the diagnosis is primarily made by exclusion, PPCM is an important entity that cannot be easily overlooked as PPCM was considered highly fatal and accounted for 4% and 14% of maternal deaths in both developed and developing countries, respectively, according to a recent meta-analysis. 6 Not to mention the devastating long-term consequences it had on previously healthy women, as the European Society of Cardiology (ESC) revealed that 54% of these patients had not fully recovered and 6% deceased after six months of follow-up. 7 In 2020, the European Society of Cardiology (ESC) developed the largest PPCM registry, which recruited 739 patients with PPCM from several regions, including Europe, Asia-Pacific, Middle East, and Africa. 7 However, owing to its rarity, PPCM data in most other countries, including China and Indonesia, are still scarce. As we completed the first full 6-month follow-up of patients with PPCM in Indonesia, which was initiated at Hasan Sadikin General Hospital, a tertiary referral hospital in the largest province in Indonesia, this study aimed to demonstrate the baseline characteristics and 6-month outcomes of patients with PPCM in Indonesia. From January 2014 to December 2021, all PPCM patients aged ≥18 years who were admitted to Dr. Hasan Sadikin General Hospital in Bandung, Indonesia, participated in this single-center, prospective cohort study. All patients included in this study provided informed consent at the beginning of the study, and those who did not provide informed consent were excluded. This study was approved by the Medical Research Ethics Committee of Dr. Hasan Sadikin General Hospital, Bandung, Indonesia, in accordance with the principles outlined in the Declaration of Helsinki. Our exclusion criteria were as follows: (1) patients diagnosed with other causes of heart failure, (2) LVEF > 50%, and (3) patients who were lost to follow-up at the conclusion of the follow-up period. The diagnosis of PPCM was confirmed if the following criteria were fulfilled: 2 (1) experienced congestive heart failure symptoms during the prepartum period or within several mont -Abstract Truncated-
medicine, general & internal